Abstract
One of the critical issues in Parkinson disease (PD) research is the identity of the specific toxic, pathogenic moiety. In PD, mutations in alpha-synuclein (αsyn) or multiplication of the SNCA gene encoding αsyn, result in a phenotype of cellular inclusions, cell death, and brain dysfunction. While the historical point of view has been that the macroscopic aggregates containing αsyn are the toxic species, in the last several years evidence has emerged that suggests instead that smaller soluble species - likely oligomers containing misfolded αsyn - are actually the toxic moiety and that the fibrillar inclusions may even be a cellular detoxification pathway and less harmful. If soluble misfolded species of αsyn are the toxic moieties, then cellular mechanisms that degrade misfolded αsyn would be neuroprotective and a rational target for drug development. In this review we will discuss the fundamental mechanisms underlying αsyn toxicity including oligomer formation, oxidative stress, and degradation pathways and consider rational therapeutic strategies that may have the potential to prevent or halt αsyn induced pathogenesis in PD.
Keywords: Alpha-synuclein, Parkinson's Disease, Chaperones, Oligomers, Heat shock proteins, oxidative stress, Degradation, Neurodegeneration, AMPA, MPTP, PINK1, Geldanamycin, Gene therapy, CHIP, Chaperone-mediated autophagy
CNS & Neurological Disorders - Drug Targets
Title: Drug Targets from Genetics: Alpha-Synuclein
Volume: 10 Issue: 6
Author(s): Karin M. Danzer and Pamela J. McLean
Affiliation:
Keywords: Alpha-synuclein, Parkinson's Disease, Chaperones, Oligomers, Heat shock proteins, oxidative stress, Degradation, Neurodegeneration, AMPA, MPTP, PINK1, Geldanamycin, Gene therapy, CHIP, Chaperone-mediated autophagy
Abstract: One of the critical issues in Parkinson disease (PD) research is the identity of the specific toxic, pathogenic moiety. In PD, mutations in alpha-synuclein (αsyn) or multiplication of the SNCA gene encoding αsyn, result in a phenotype of cellular inclusions, cell death, and brain dysfunction. While the historical point of view has been that the macroscopic aggregates containing αsyn are the toxic species, in the last several years evidence has emerged that suggests instead that smaller soluble species - likely oligomers containing misfolded αsyn - are actually the toxic moiety and that the fibrillar inclusions may even be a cellular detoxification pathway and less harmful. If soluble misfolded species of αsyn are the toxic moieties, then cellular mechanisms that degrade misfolded αsyn would be neuroprotective and a rational target for drug development. In this review we will discuss the fundamental mechanisms underlying αsyn toxicity including oligomer formation, oxidative stress, and degradation pathways and consider rational therapeutic strategies that may have the potential to prevent or halt αsyn induced pathogenesis in PD.
Export Options
About this article
Cite this article as:
M. Danzer Karin and J. McLean Pamela, Drug Targets from Genetics: Alpha-Synuclein, CNS & Neurological Disorders - Drug Targets 2011; 10 (6) . https://dx.doi.org/10.2174/187152711797247867
DOI https://dx.doi.org/10.2174/187152711797247867 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model
Current Drug Targets Phenolic Acids Exert Anticholinesterase and Cognition-Improving Effects
Current Alzheimer Research The Forkhead Transcription Factor FOXO3a Controls Microglial Inflammatory Activation and Eventual Apoptotic Injury through Caspase 3
Current Neurovascular Research PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance
Current Cancer Drug Targets Real Time Analysis of Neurotransmitters in the Brain Using a Micro-Electrode System
Current Neurovascular Research Genetically Modified Dendritic Cells for Cancer Immunotherapy
Current Gene Therapy Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research Receptor Dimerization - Rationale for the Design of Bivalent Ligands
Current Topics in Medicinal Chemistry Endocytosis, Intracellular Traffic and Fate of Cell Penetrating Peptide Based Conjugates and Nanoparticles
Current Pharmaceutical Design Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma
Recent Patents on Anti-Cancer Drug Discovery Sympathetic Signaling in Angiogenesis: Implications for Cancer Progression
Current Cancer Therapy Reviews Role of Hydrogen Sulfide in Systemic and Pulmonary Hypertension: Cellular Mechanisms and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry Hedgehog Signaling and Urological Cancers
Current Drug Targets Induced Pluripotent Stem Cells as a Model for Accelerated Patient- and Disease-specific Drug Discovery
Current Medicinal Chemistry Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Cytokine Network: New Targeted Therapy for Pancreatic Cancer
Current Pharmaceutical Design Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening Co-Treatment With Copper Compounds Dramatically Decreases Toxicities Observed With Cisplatin Cancer Therapy And The Anticancer Efficacy Of Some Copper Chelates Supports The Conclusion That Copper Chelate Therapy May Be Markedly More Effective And Less Toxic Than Cisplatin Therapy
Current Medicinal Chemistry High Glucose Enhances Neurotoxicity and Inflammatory Cytokine Secretion by Stimulated Human Astrocytes
Current Alzheimer Research